Please assess the completion status of the following clinical trial:

Trial Title: OPTIMA-TBI Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals presenting to the emergency department (ED) within 24 hours of injury, who meet the American Congress of Rehabilitation Medicine (ACRM)'s definition of having mild traumatic brain injury (mTBI) will be eligible~* The ACRM defines mTBI as a traumatically-induced physiological disruption of brain function as a consequence of the head being struck, striking an object, or undergoing an acceleration/deceleration movement without direct external head trauma and resulting in at least one of the following:~* any period of loss of consciousness (LOC)~* any loss of memory for events immediately before or after the injury~* any alteration in mental state at the time of the injury (eg, feeling dazed, disoriented, or confused)~* focal neurological deficit(s) that may or may not be transient~Exclusion Criteria:~* GCS\<13 at any time during ED stay.~* Significant polytrauma including: bony fracture or solid organ injury~* Study medication cannot be administered within 24 hours of injury~* Patient cannot be relied on to complete follow-up (i.e. no reliable telephone number, substance dependence, homeless)~* Cannot communicate in English~* Take an anticoagulant (coumadin or a novel oral anticoagulant) daily~* Age less than 18 years or greater than 65 years~* Patients already taking fish oil supplements daily~* History of cognitive impairment~* Allergic to fish/fish oil~* Pregnant women (self-reported)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Omega-3 Polyunsaturated Fatty Acid Treatment Arm (Type: EXPERIMENTAL): Participants randomized to this study arm will receive 6g DHA+EPA for one month followed by 1.2 g DHA+EPA for two months. Capsules contain fish oil 1000 mg (contains 500 mg DHA \& 100 mg EPA) or placebo capsules.
- Placebo Arm (Type: PLACEBO_COMPARATOR): Participants randomized to this study arm will receive placebo drug for 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).